Table 2 Correlation between PIM-1 expression and clinicopathological features in patients with acute myeloid leukemia (AML)
From: PIM-1 mRNA expression is a potential prognostic biomarker in acute myeloid leukemia
Clinicopathological feature | Total | mRNA expression of PIM-1 | P value | |
|---|---|---|---|---|
Low (n = 38, 32.2%) | High (n = 80, 67.8%) | |||
Gender | ||||
Male | 62 | 17 (27.5%) | 45 (72.5%) | 0.1522 |
Female | 56 | 21 (37.5%) | 35 (62.5%) | |
Age (years) | ||||
≤47 | 67 | 21 (31.3%) | 46 (68.7%) | 0.3469 |
>47 | 51 | 17 (33.3%) | 34 (66.7%) | |
WBC (×109) | ||||
<10 | 57 | 16 (28.1%) | 41 (71.9%) | 0.9206 |
>10 | 61 | 22 (36.1%) | 39 (63.9%) | |
Hb (g/L) | ||||
<81 | 66 | 18 (27.3%) | 48 (72.7%) | 0.7689 |
>81 | 52 | 20 (38.5%) | 32 (61.5%) | |
PLT (×109) | ||||
<57 | 75 | 28 (37.3%) | 47 (62.7%) | 0.7321 |
>57 | 43 | 10 (23.3%) | 33 (76.7%) | |
Blasts (%) | ||||
<62 | 54 | 14 (25.9%) | 40 (74.1%) | 0.1762 |
>62 | 64 | 24 (37.5%) | 40 (62.5%) | |
FAB classification | ||||
M1 | 4 | 1 (25%) | 3 (75%) | 0.1162 |
M2 | 35 | 15 (42.9%) | 20 (57.1%) | |
M4 | 37 | 11 (29.7%) | 26 (70.3%) | |
M5 | 37 | 9 (24.3%) | 28 (75.7%) | |
M6 | 5 | 2 (40%) | 3 (60%) | |
Risk stratification | ||||
Low risk | 49 | 24 (48.9%) | 25 (51.1%) | 0.0029a |
Intermediate risk | 28 | 9 (32.1%) | 19 (67.2%) | |
High risk | 41 | 5 (12.2%) | 36 (87.8%) | |
Treatment | ||||
Chemotherapy | 87 | 26 (29.9%) | 61 (70.1%) | 0.9098 |
HSCT | 31 | 12 (38.7%) | 19 (61.3%) | |
Vital status | ||||
Survival | 27 | 14 (51.9%) | 13 (48.1%) | 0.0322a |
Death | 91 | 24 (26.4%) | 67 (73.6%) | |